TICKERS: IOVA

Cell Therapy for Melanoma Impresses in
Phase 2

Research Report

Source:

Positive clinical data for this U.S. company's immunotherapy for metastatic melanoma are both encouraging and impressive, says one analyst.

Joe Pantginis of Rodman & Renshaw commented on Iovance Biotherapeutics Inc.'s (IOVA:NASDAQ) progress in an Aug. 2 research report, noting data presented at the American Society of Clinical Oncology (ASCO) conference in June highlighted the company's "technical capabilities and ability to reproduce positive clinical results."

With the ASCO presentation, the company "took a positive step towards answering two primary questions: 1) can Iovance deliver the first internally driven efficacy of TILs (tumor infiltrating lymphocytes; T cells) in melanoma; and 2) can Iovance internally recapitulate the NCI (National Cancer Institute) [six-week] manufacturing process," Pantginis wrote. "Data from 16 patients were presented and showed an overall response rate of 29%, including one [complete response] (achieved at six months post a single TIL treatment and continuing beyond 15 months). Reductions in target tumor lesions were observed in 77% of patients."

Pantginis wrote that he found the data "encouraging and impressive."

The analyst also described ongoing research at the company, formerly known as Lion Biotherapeutics.

The second cohort in Iovance's LN-144 study "is up and running; data from both cohorts expected by YE17," Pantginis wrote.

The two cohorts are receiving cells produced via different manufacturing processes, the second of which "offers a reduced timeframe from tumor excision to TIL infusion of approximately three weeks. In addition, the TILs for cohort two are being cryopreserved and then thawed before infusion, which allows for additional flexibility in scheduling," the analyst explained.

"With regards to comparison of the two manufacturing processes, Iovance plans to look for similar response rates between the two cohorts, which it believes its in vitro assays are predictive of equivalency," Pantginis stated. Once data is analysed at the end of 2017, the company "plans to choose the manufacturing process to be utilized for clinical studies going forward."

Pantginis also noted that "at the end of 1Q17, the manufacturing capacity was sufficient to provide TILs for all clinical programs including the three Iovance sponsored studies, a study at MD Anderson, and a future study in collaboration with MedImmune which is expected to initiate in early 2018."

Additionally, studies in "melanoma and cervical cancer are to be expanded into the E.U. (separate from Karolinska collaborations), which includes the existing ongoing LN-144 trial for metastatic melanoma, and LN-145 for cervical cancer. In 3Q17, Iovance plans to submit a clinical trial authorization (CTA) for these trials in the E.U.," Pantginis stated.

Rodman & Renshaw has a Buy rating and target price of $16 per share on Iovance. The stock is currently trading at approximately $5.60.

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in this article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.




Get Our Streetwise Reports Newsletter Free

A valid email address is required to subscribe